Investigational drug · Phase 3
SCTB41
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
6
Any phase or sponsor naming "SCTB41"
First trial start
2024
Oct 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCTB41", any sponsor or status.
Conditions studied
As listed on its trial records.
- NHL - Non-Hodgkin's Lymphoma
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Advanced Malignant Solid Tumor
- Advanced Malignant Solid Tumors
- Advanced Malignant Solid Tumours
- Double Blind
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "SCTB41" as an intervention, largest first.
Sinocelltech Ltd.Industry
NCT06600022 · 441 participants (planned) · Start Oct 10, 2024 · Primary completion Apr 30, 2027
Drug: SCTB41 · For: Advanced Malignant Solid Tumours
Sites: Guangzhou, China
- SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerPivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07662395 · 410 participants (planned) · Start May 9, 2026 · Primary completion Jan 24, 2030
Drug: SCTB41; Tislelizumab and 5 more · For: Double Blind
Sites: Guangzhou, China
- Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid TumoursNot yet recruiting
Sinocelltech Ltd.Industry
NCT07594028 · 126 participants (planned) · Start May 30, 2026 · Primary completion May 30, 2029
Drug: SCTB41+SCTB39-1 · For: Advanced Malignant Solid Tumor
Sinocelltech Ltd.Industry
NCT07665970 · 112 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2029
Drug: SCTB41+SCTB39G · For: Advanced Malignant Solid Tumors
- SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin LymphomaNot yet recruiting
Sinocelltech Ltd.Industry
NCT07819188 · 90 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2028
Drug: SCTB35 injection; SCTB41 · For: NHL - Non-Hodgkin's Lymphoma
Sites: Tianjing, China
Sinocelltech Ltd.Industry
NCT07609251 · 90 participants (planned) · Start May 2026 · Primary completion Oct 2028
Drug: SCTB41; docetaxel · For: NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NHL - Non-Hodgkin's Lymphoma
- SCTB35Phase 34 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, Follicular Lymphoma (FL), System Lupus Erythematosus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.